Blood platelet RNA yields a new diagnostic prospective for accurate detection and staging of pancreatic ductal adenocarcinoma

Boyd, Lenka N.C.; Meijer, Laura L.; Veld, Sjors In ’t; Large, T. Le; Best, Myron G.; Lelij, Ewoud van der; Dwarshuis, Govert; Sol, Nik; Mantini, G.; Capula, Mjriam; Frampton, Adam E.; Morelli, Luca; Arkani, Mohammad; Post, Edward P.; Zonderhuis, B.; Daams, Freek; Besselink, Marc G.; Bijlsma, Maarten F.; Giovannetti, Elisa; Würdinger, Thomas; Kazemier, Geert

doi:10.1016/j.pan.2020.07.253

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asghar [109] PI3K, AKT qRT-PCR 12 10 AUC were 0.9286 and 0. 8751, respectively Waqar [124] CTNNB1, SERPIND1, SPINK1 qRT-PCR 20 20 Differentiating from late-stage cirrhotic nodules: the AUC of CTNNB1, SERPIND1, SPINK1 and their combination for 0.94, 0.88, 0.89, and 1.0 respectively Pancreatic cancer Boyd [114] NA RNA-seq NA NA Differentiate from late stages (AUC = 0.91) Large [115] NA RNA-seq NA NA Classified early-stage patients correctly and distinguished them from advanced and benign diseases MGUS Van Eijs [125] 1371 genes RNA-Seq 24 29 Differentiate from healthy controls (P < .0001) Melanoma…”

Section: Myeloproliferative Neoplasmsmentioning

confidence: 99%

“…Validation set: Se = 100%, Sp = 100%, Ac = 100% Boyd [114] NA RNA-seq 112 60 Se = 71%, Sp = 98%, AUC = 0.93. Large [115] NA RNA-seq 135 322 Controls: 250 healthy controls and 72 benign pancreatobiliary disease patients: Ac >90% In 't Veld [105] 493 genes RNA-seq 126 723 AUC = 0.81 Nasopharyngeal carcinoma Sun [116] miR-18a-3p qRT-PCR 54 36 Se = 87%, Sp = 72.7%, AUC = 0.841 Wang [100] miR-34c the control group, which may have undermined the evaluation of platelet RNA.…”

Section: Patients Controlsmentioning

confidence: 99%

See 1 more Smart Citation

A narrative review for platelets and their RNAs in cancers: New concepts and clinical perspectives

Xiang

Xiang²,

Zhang

et al. 2022

Medicine

View full text Add to dashboard Cite

Recent years have witnessed a growing body of evidence suggesting that platelets are involved in several stages of the metastatic process via direct or indirect interactions with cancer cells, contributing to the progression of neoplastic malignancies. Cancer cells can dynamically exchange components with platelets in and out of blood vessels, and directly phagocytose platelets to hijack their proteome, transcriptome, and secretome, or be remotely regulated by metabolites or microparticles released by platelets, resulting in phenotypic, genetic, and functional modifications. Moreover, platelet interactions with stromal and immune cells in the tumor microenvironment lead to alterations in their components, including the ribonucleic acid (RNA) profile, and complicate the impact of platelets on cancers. A deeper understanding of the roles of platelets and their RNAs in cancer will contribute to the development of anticancer strategies and the optimization of clinical management. Encouragingly, advances in high-throughput sequencing, bioinformatics data analysis, and machine learning have allowed scientists to explore the potential of platelet RNAs for cancer diagnosis, prognosis, and guiding treatment. However, the clinical application of this technique remains controversial and requires larger, multicenter studies with standardized protocols. Here, we integrate the latest evidence to provide a broader insight into the role of platelets in cancer progression and management, and propose standardized recommendations for the clinical utility of platelet RNAs to facilitate translation and benefit patients.

show abstract